Balaxi Pharmaceuticals Limited

As of June 30, 2026, Balaxi Pharmaceuticals Limited carries a market capitalization of 1.32B, placing it among publicly traded companies globally. Its enterprise value stands at 1.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Balaxi Pharmaceuticals Limited has 55.21M shares outstanding.

As of June 30, 2026, Balaxi Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 52.48.

As of June 30, 2026, Balaxi Pharmaceuticals Limited trades at an EV/EBITDA multiple of 14.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.30 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.32B versus a market cap of 1.32B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 47.88M in revenue per employee across its workforce of 58.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Balaxi Pharmaceuticals Limited recorded 40.54M in income tax expense. That works out to an effective tax rate of 62.58, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 64.78M, leaving 24.24M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Balaxi Pharmaceuticals Limited's stock has declined approximately 50.21% over the past 52 weeks. The 50-day moving average sits at 23.00, while the 200-day moving average is 23.45.

Over the twelve months ended June 30, 2026, Balaxi Pharmaceuticals Limited generated 2.80B in revenue and converted that into 24.24M in net income, yielding earnings per share of 0.46. EBITDA reached 90.42M, while operating income came in at 65.03M.

Over the twelve months ended June 30, 2026, Balaxi Pharmaceuticals Limited posted a gross margin of 44.85, reflecting its pricing power and cost economics. The operating margin of 2.32 and net profit margin of 0.87 provide insight into operational efficiency.

Balaxi Pharmaceuticals Limited's most recent stock split took place on May 30, 2024 with a 1:5 split ratio.